| Market Cap | 1.65M | P/E | 0.01 | EPS this Y | 53.30% | Ern Qtrly Grth | - |
| Income | -22.53M | Forward P/E | -0.67 | EPS next Y | 94.90% | 50D Avg Chg | -21.00% |
| Sales | 1.36M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -86.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | 2.00 | Quick Ratio | 0.28 | Shares Outstanding | 554.88K | 52W Low Chg | 92.00% |
| Insider Own | 0.32% | ROA | -64.75% | Shares Float | 497.38K | Beta | 1.47 |
| Inst Own | 7.34% | ROE | - | Shares Shorted/Prior | 88.06K/14.29K | Price | 2.98 |
| Gross Margin | -105.52% | Profit Margin | - | Avg. Volume | 2,137,636 | Target Price | 24.00 |
| Oper. Margin | -3,011.70% | Earnings Date | Mar 14 | Volume | 210,482 | Change | -1.47% |
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
| Oppenheimer | Outperform | May 11, 20 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HENWOOD GERALDINE | President and CEO President and CEO | Dec 15 | Buy | 2.5476 | 1,200 | 3,057 | 2,427 | 12/19/22 |